Clorox (CLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

04.02.25 01:00 Uhr

Werte in diesem Artikel
Aktien

155,20 EUR 0,00 EUR 0,00%

90,50 EUR -2,50 EUR -2,69%

Indizes

5.994,6 PKT -46,0 PKT -0,76%

For the quarter ended December 2024, Clorox (CLX) reported revenue of $1.69 billion, down 15.3% over the same period last year. EPS came in at $1.55, compared to $2.16 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.64 billion, representing a surprise of +3.12%. The company delivered an EPS surprise of +11.51%, with the consensus EPS estimate being $1.39.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Clorox performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Organic Revenue Growth - Health and Wellness: -13% compared to the -19.8% average estimate based on four analysts. Organic Revenue Growth - International: 6% versus the four-analyst average estimate of -4%. Organic Revenue Growth - Lifestyle: -16% versus the four-analyst average estimate of -26.3%. Organic Revenue Growth - Household: -11% versus -8.5% estimated by four analysts on average. Organic Sales Growth: -9% compared to the -14.1% average estimate based on four analysts. Net Revenue- Health and Wellness: $628 million versus the four-analyst average estimate of $577.80 million. The reported number represents a year-over-year change of -12.8%. Net Revenue- International: $274 million versus the four-analyst average estimate of $259.29 million. The reported number represents a year-over-year change of -11.9%. Net Revenue- Lifestyle: $338 million versus the four-analyst average estimate of $297.10 million. The reported number represents a year-over-year change of -16.1%. Net Revenue- Household: $446 million versus $459.38 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -11.2% change. Income before income taxes- Health and Wellness: $193 million compared to the $176.97 million average estimate based on two analysts. Income before income taxes- Corporate and Other: -$74 million compared to the -$98.17 million average estimate based on two analysts. Income before income taxes- International: $21 million versus $29.33 million estimated by two analysts on average. View all Key Company Metrics for Clorox here>>>Shares of Clorox have returned -2.6% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Clorox Company (CLX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Clorox

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Clorox

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Clorox Co., The

Wer­bung

Analysen zu Clorox Co., The

DatumRatingAnalyst
02.05.2019Clorox HoldDeutsche Bank AG
14.12.2017Clorox HoldDeutsche Bank AG
09.01.2017Clorox Equal WeightBarclays Capital
16.12.2016Clorox OutperformBMO Capital Markets
03.11.2016Clorox Sector PerformRBC Capital Markets
DatumRatingAnalyst
16.12.2016Clorox OutperformBMO Capital Markets
06.02.2015Clorox BuyArgus Research Company
05.12.2014Clorox BuyArgus Research Company
09.07.2012Clorox kaufenEuro am Sonntag
16.02.2011Clorox outperformRBC Capital Markets
DatumRatingAnalyst
02.05.2019Clorox HoldDeutsche Bank AG
14.12.2017Clorox HoldDeutsche Bank AG
09.01.2017Clorox Equal WeightBarclays Capital
03.11.2016Clorox Sector PerformRBC Capital Markets
05.05.2016Clorox NeutralB. Riley & Co., LLC
DatumRatingAnalyst
04.05.2016Clorox SellUBS AG
03.11.2015Clorox SellUBS AG
07.10.2015Clorox UnderweightBarclays Capital
23.09.2014Clorox SellB. Riley & Co., LLC
03.02.2006Update Clorox Co., The: SellOppenheimer

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Clorox Co., The nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"